Ingimarsson Johann P, Sigurdsson Martin I, Hardarson Sverrir, Petursdottir Vigdis, Jonsson Eirikur, Einarsson Gudmundur V, Gudbjartsson Tomas
Departments of Urology and Surgery, Landspitali University Hospital; Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
BMC Urol. 2014 Aug 31;14:72. doi: 10.1186/1471-2490-14-72.
The observed low metastatic potential and favorable survival of small incidentally detected renal cell carcinomas (RCCs) have been a part of the rationale for recommending partial nephrectomy as a first treatment option and active surveillance in selected patients. We examined the relationship between tumor size and the odds of synchronous metastases (SMs) (primary outcome) and disease specific survival (secondary outcome) in a nationwide RCC registry.
Retrospective study of the 794 RCC patients diagnosed in Iceland between 1971 and 2005. Histological material and TNM staging were reviewed centrally. The presence of SM and survival were recorded. Cubic spline analysis was used to assess relationship between tumor size and probability of SM. Univariate and multivariate statistics were used to estimate prognostic factors for SM and survival.
The probability of SM increased in a non-linear fashion with increasing tumor size (11, 25, 35, and 50%) for patients with tumors of ≤4, 4.1-7.0, 7.1-10.0, and >10 cm, respectively. On multivariate analysis, tumor size was an independent prognostic factor for disease-specific survival (HR = 1.05, 95% CI 1.02-1.09, p < 0.001), but not for SM.
Tumor size affected the probability of disease-specific mortality but not SM, after correcting for TNM staging in multivariate analysis. This confirms the prognostic ability of the 2010 TNM staging system for renal cell cancer in the Icelandic population.
偶然发现的小肾癌(RCC)具有较低的转移潜能和良好的生存率,这是推荐部分肾切除术作为首选治疗方案以及对特定患者进行主动监测的部分依据。我们在一个全国性的RCC登记处研究了肿瘤大小与同步转移(SMs)几率(主要结局)和疾病特异性生存(次要结局)之间的关系。
对1971年至2005年在冰岛诊断的794例RCC患者进行回顾性研究。对组织学材料和TNM分期进行集中审查。记录SM的存在情况和生存情况。使用三次样条分析评估肿瘤大小与SM概率之间的关系。使用单变量和多变量统计方法估计SM和生存的预后因素。
肿瘤大小≤4 cm、4.1 - 7.0 cm、7.1 - 10.0 cm和>10 cm的患者,SM的概率分别以非线性方式随肿瘤大小增加而增加(分别为11%、25%、35%和50%)。多变量分析显示,肿瘤大小是疾病特异性生存的独立预后因素(HR = 1.05,95% CI 1.02 - 1.09,p < 0.001),但不是SM的独立预后因素。
在多变量分析中校正TNM分期后,肿瘤大小影响疾病特异性死亡概率,但不影响SM。这证实了2010年TNM分期系统对冰岛人群肾细胞癌的预后评估能力。